Continuous recyclable enzymatic process for preparation of sitagliptin or salts thereof

The continuous recyclable enzymatic process for Sitagliptin production addresses inefficiencies and cost issues by recycling transaminase enzymes and avoiding buffers, achieving high purity and controlling genotoxic impurities, thus making the process economically viable and industrially scalable.

WO2024252346A1PCT designated stage expired Publication Date: 2024-12-12AMI LIFESCIENCES PTE LTD

Patent Information

Application Number
PCT/IB2024/055586
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-06-08
Filing Date
2024-06-07
Publication Date
2024-12-12

AI Technical Summary

Technical Problem

Existing processes for Sitagliptin production are inefficient due to multiple synthetic steps, high costs associated with immobilized enzymes, and challenges in controlling genotoxic impurities like nitrosamine, which makes them unviable at an industrial scale.

Method used

A continuous recyclable enzymatic process using transaminase enzyme without immobilization or additional buffers, allowing for repeated recycling of the enzyme up to five times, eliminating the need for additional solvents and buffers, and effectively controlling genotoxic impurities to achieve high purity Sitagliptin or its salts.

Benefits of technology

This process significantly reduces production costs, maintains high yield and enzyme activity, and achieves 99.9% purity of Sitagliptin or its salts while controlling genotoxic impurities below 0.3 ppm, making it industrially viable and cost-effective.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000002_0001
    Figure IMGF000002_0001
  • Figure IMGF000004_0001
    Figure IMGF000004_0001
  • Figure IMGF000005_0001
    Figure IMGF000005_0001
Patent Text Reader

Abstract

The present invention relates to an efficient and industrially scalable continuous recyclable enzymatic process for preparation of Sitagliptin or salts thereof. The present invention also relates to a process for the preparation of Sitagliptin hydrochloride or hydrate thereof. The present invention also relates to a process for the preparation of Sitagliptin phosphate or hydrate thereof.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CONTINUOUS RECYCUABUE ENZYMATIC PROCESS FOR

[0002] PREPARATION OF SITAGLIPTIN OR SAETS THEREOF

[0003] FIELD OF THE INVENTION:

[0004] The present invention relates to an efficient and industrially scalable continuous recyclable enzymatic process for preparation of Sitagliptin or salts thereof.

[0005] The present invention also relates to a process for the preparation of Sitagliptin hydrochloride monohydrate or hydrate thereof.

[0006] The present invention also relates to a process for the preparation of Sitagliptin phosphate or hydrate thereof.

[0007] BACKGROUND OF THE INVENTION:

[0008] Sitagliptin is chemically known as 7-[(3R)-3-amino-l-oxo-4-(2,4,5- trifluorophenyl) butyl]- 5,6,7,8-tetrahydro-3-(trifluoromethyl)-l,2,4-triazolo[4,3-a] pyrazine, represented by compound of Formula-I:

[0009] [Formula-I]

[0010] Sitagliptin is a dipeptidyl peptidase 4 (DPP-4) inhibitor and used to improve glycemic control in patients with type-2 diabetes mellitus. Sitagliptin is sold under the trade name JANUVIA® as monotherapy and JANUMET® in combination with Metformin hydrochloride.

[0011] US patent number US 6699871 (herein after US’871) first discloses Sitagliptin and salts thereof. US’871 also discloses a process for the preparation of Sitagliptin. However, large number of synthetic steps are required for the preparation of Sitagliptin which makes the process unpractical. US ’871 does not discloses synthesis of Sitagliptin by enzymatic route.

[0012] US patent number US 8293507 (herein after US ’507) discloses a process for the preparation of Sitagliptin from ketoamide substrate using transaminase enzyme, amine donor, buffer and cofactor in water and water miscible organic solvent. However, US ’507 process suffers from the major drawback that transaminase enzyme can be used only once making the process costlier and recovery of solvent is also difficult. Additionally, carbonyl by-product which has been formed during the reaction must be removed by purging the reaction solution with a non-reactive gas or by applying vacuum. Furthermore, process reported in US ’507 requires additional buffer which increases the cost of production.

[0013] US patent numbers US 9587229 and US 9523107 discloses a process for the preparation of Sitagliptin from its ketoamide substrate using immobilized transaminases in the presence of an amino group donor and buffer. However, process using immobilized enzymes is expensive as they need an exclusive dedicated infrastructure which is expensive needing extra space, material, and utilities. In addition, it requires specific material and additional process step which is time consuming. For immobilisation process sophisticated process equipment is needed. In the production process other problems arise, such as increased risk of contamination, need for extra control of temperature and pH, and substrate purity. As evident from the above facts, the reuse of immobilized enzymes is also not economical thus not viable at industrial scale.

[0014] Indian patent IN 410796 (herein after IN’796) discloses process for the preparation of Sitagliptin from ketoamide substrate using transaminase enzyme, amine donor, cofactor, and buffer.

[0015] Major drawback of IN’796 process is during the reaction, acetone which has been generated as a by-product has to be removed under reduced pressure to enable the reaction to proceed to completion. Further, IN’796 process requires buffer which increases the cost of production. Additionally, IN’796 is silent about the control of genotoxic impurity. Therefore, process is not industrially viable.

[0016] To overcome the disadvantages mentioned above, inventors of the present invention have developed a novel and improved continuous recyclable enzymatic process for the preparation of Sitagliptin or its salts from Ketoamide substrate using transaminase enzyme in absence of buffer.

[0017] To the surprise, inventors have found that the process of recycling of enzyme can be repeated for at least five times to produce highly pure Sitagliptin or its salts without loss in yield or enzyme activity and without the need of additional topping of enzyme, cofactor as well as water miscible organic solvent to the reaction mass, thereby making the process substantially economical.

[0018] The process also avoids immobilization of enzyme thereby reducing the additional cost of immobilization process including exclusive dedicated infrastructure, specific material, sophisticated process equipment and additional process steps needed for the same.

[0019] Further, process avoids the use of buffer, thereby additionally reducing the cost of production.

[0020] In addition, current process avoids the additional step of removal of acetone byproduct from the reaction mass without affecting the reaction to proceed to completion.

[0021] The current process also provides excellent control of genotoxic impurities inclusive of nitrosamine impurity, Nitroso-STG-19 (known as NTTP) represented by the structure given below as Formula-A, [Formula-A]

[0022] FDA recently became aware of this nitrosamine impurity in certain samples of sitagliptin and has also set the acceptable intake limit of 37 ng per day, and up to 246.7 ng per day. NTTP belongs to the nitrosamine class of compounds, some of which have been classified as probable or possible human carcinogens (substances that could cause cancer), based on laboratory tests. Hence, it is very important to control this NTTP impurity in Sitagliptin API. Current process controls the amount of NTTP impurity in Sitagliptin or its salts below the level of 0.3 ppm and provides highly pure and stable Sitagliptin or its salts having 99.9% purity without carrying out any additional purification or crystallization procedure.

[0023] OBJECT OF THE INVENTION:

[0024] The main object of the present invention is to provide an efficient, improved, economical and industrially advantageous continuous recyclable enzymatic process for the preparation of Sitagliptin or its salts with high purity.

[0025] Another object of the present invention is to provide a process for the preparation of Sitagliptin hydrochloride monohydrate or hydrate thereof.

[0026] The present invention also relates to a process for the preparation of Sitagliptin phosphate or hydrate thereof.

[0027] SUMMARY OF INVENTION:

[0028] First aspect of the present invention is to provide a continuous recyclable enzymatic process for the preparation of highly pure Sitagliptin of Formula-I,

[0029] [Formula-I] or pharmaceutically acceptable salts thereof comprising the steps of: a) reacting compound of Formula-II,

[0030] [Formula-II] with amine donor using transaminase enzyme, cofactor in water and water miscible organic solvent in absence of buffer; b) adding water immiscible organic solvent to the reaction mixture obtained in step a); c) separating the organic layer and aqueous layer from mixture obtained in step b); d) obtaining highly pure Sitagliptin of Formula-I or pharmaceutically acceptable salt thereof from the organic layer obtained in step c); and e) continuously recycling aqueous layer obtained in step c) to produce next batches of Sitagliptin of Formula-I or pharmaceutically acceptable salt thereof by reacting the said aqueous layer with compound of the Formula- II followed by steps b) to d).

[0031] Second aspect of the present invention is to provide a process for the preparation of Sitagliptin hydrochloride monohydrate of Formula- III

[0032] [Formula-Ill] comprising the steps of: a) dissolving Sitagliptin hydrochloride of Formula- IV

[0033] [Formula-IV] in methanol and water by heating up to reflux temperature; b) adding methyl tert-butyl ether to the mixture; and c) isolating Sitagliptin hydrochloride monohydrate of Formula IV.

[0034] DEFINITION:

[0035] All temperatures used herein are in degree Celsius unless specified otherwise.

[0036] All ranges recited herein include the endpoints, including those that recite a range "between" two values.

[0037] As used herein, "comprising" means the elements recited, or their equivalents in structure or function, plus any other element or elements that may or may not be recited.

[0038] The terms "having" and "including" are also to be construed as open ended unless the context suggests otherwise.

[0039] The term "about", as used herein, refers to any value which lies within the range defined by a number up to ±10% of the value.

[0040] The term “highly pure” refers to the purity greater than 99.9%, more preferably 99.99% by HPLC (High-performance liquid chromatography)

[0041] The term “pharmaceutically acceptable salts thereof’ includes various salts of Sitagliptin such as hydrochloride, hydrobromide, phosphate, oxalate, citrate, maleate, and the like.

[0042] DETAILED DESCRIPTION OF INVENTION: The invention will now be described in detail in connection with certain preferred embodiments, so that various aspects thereof may be fully understood and appreciated.

[0043] The present invention provides a novel, efficient and industrially advantageous process for the preparation of highly pure Sitagliptin of Formula-I or salts thereof.

[0044] First embodiment of the present invention provides a continuous recyclable enzymatic process for the preparation of highly pure Sitagliptin of Formula-I,

[0045] [Formula-I] or pharmaceutically acceptable salts thereof comprising the steps of: a) reacting compound of Formula-II,

[0046] [Formula-II] with amine donor using transaminase enzyme, cofactor in water and water miscible organic solvent in absence of buffer; b) adding water immiscible organic solvent to the reaction mixture obtained in step a); c) separating the organic layer and aqueous layer from mixture obtained in step b); d) obtaining highly pure Sitagliptin of Formula-I or pharmaceutically acceptable salt thereof from the organic layer obtained in step c); and e) continuously recycling aqueous layer obtained in step c) to produce next batches of Sitagliptin of Formula-I or pharmaceutically acceptable salt thereof by reacting the said aqueous layer with compound of the Formula- II followed by steps b) to d).

[0047] In the first embodiment of step a), compound of Formula-II used as a starting material for the preparation of Sitagliptin of Formula-I can be prepared by process known in the prior art.

[0048] In the first embodiment of step a), amine donor can be selected from the group consisting of monoisopropylamine, isobutyl amine, 2-methyl benzyl amine, diphenyl methyl amine, any C-substituted isopropyl amine, alanine, orthoxylenediamine, 1 -phenylethylamine, 3-aminocyclohexa-l,5-dienecarboxylic acid, 1,2-diaminoethane, 1,4-diaminobutane and 1,5-diaminopentane.

[0049] In the first embodiment of step a), molar equivalent of amine donor with respect to compound of the Formula-II can be 4.0 to 5.0.

[0050] In the first embodiment of step a), transaminase enzyme can be selected from recombinant or genetically engineered transaminase enzyme.

[0051] Transaminase enzyme may refer as per the enzyme disclosed in US8921079.

[0052] In the first embodiment of step a), loading of transaminase enzyme with respect to compound of the Formula-II can be 3% to 5% by weight.

[0053] In the first embodiment of step a), cofactor can be selected from the group consisting of Vitamin B6 family including pyridoxal, pyridoxine, pyridoxamine and their respective phosphorylated derivatives such as pyridoxine 5'-phosphate, pyridoxal 5'-phosphate and pyridoxamine 5'-phosphate.

[0054] In the first embodiment of step a), cofactor used with respect to compound of the Formula-II can be 0.3% to 0.7% by weight.

[0055] In the first embodiment of step a), water miscible organic solvent can be selected from the group consisting of dimethyl sulfoxide (DMSO), ethyl acetate, chloroform, methylene dichloride (MDC), acetone, methanol, ethanol, or isopropanol. In the first embodiment of step a), volume of solvent with respect to compound of the Formula- II can be 2.5 volume to 3.5 volume.

[0056] In the first embodiment of step a), volume of water with respect to compound of the Formula- II can be 2.5 volume to 3.5 volume.

[0057] In the first embodiment of step a), reaction of compound of Formula-II with amine donor using transaminase enzyme, cofactor in water and water miscible organic solvent can be carried out at 40°C to 60°C.

[0058] In the first embodiment of step a), reaction of compound of Formula-II with amine donor using transaminase enzyme, cofactor in water and water miscible organic solvent can be carried out for 12 hours to 24 hours.

[0059] In the first embodiment of step a), reaction of compound of Formula-II with amine donor using transaminase enzyme, cofactor in water and water miscible organic solvent can be carried out by maintaining pH in the range of 9.0 to 11.0.

[0060] After completion of reaction of step a), resulting reaction mixture can be cooled to 20°C to 30°C to obtain a reaction mixture of step a).

[0061] In the first embodiment of step b), water immiscible organic solvent can be added to reaction mixture obtained in step a) at 20°C to 30°C.

[0062] In the first embodiment of step b), water immiscible organic solvent can be selected from the group consisting of alkyl ester such as ethyl acetate, isopropyl acetate, isobutyl acetate, tertiary butyl acetate or mixture thereof; ether such as diisopropyl ether, methyl isopropyl ether, methyl tert-butyl ether (MTBE) or mixture thereof; water immiscible alcohols such as n-butanol, tert-butanol, cyclohexanol or mixtures thereof and 2-methyl tetrahydrofuran or mixture thereof.

[0063] The mixture obtained in step b) can be stirred and allowed to separate aqueous layer and organic layer as per the step c) of first embodiment.

[0064] In the first embodiment of step c), organic layer is taken for step d).

[0065] In the first embodiment of step c), aqueous layer is taken for step e). In the first embodiment of step c), separated aqueous layer comprises amine donor, cofactor, transaminase enzyme, water, and water miscible organic solvent.

[0066] In the first embodiment of step d), Sitagliptin of Formula-I or pharmaceutically acceptable salt thereof can be obtained from organic layer.

[0067] In the first embodiment of step d), Sitagliptin of Formula-I can be obtained from organic layer by any technique of isolation known in the prior art including but not limited to distillation, distillation under reduced pressure, precipitation, crystallization, centrifugation etc.

[0068] Alternatively, organic layer containing Sitagliptin of Formula-I can be taken as such for the preparation of its salt.

[0069] In the first embodiment of step d), pharmaceutically acceptable salt of Sitagliptin of Formula-V,

[0070] “wherein HA is pharmaceutically acceptable acid”

[0071] Formula-V can be obtained by the process comprising the steps of: i) reacting Sitagliptin of Formula-I with pharmaceutically acceptable acid (HA) in the presence of organic solvent; ii) isolating pharmaceutically acceptable salt of Sitagliptin of Formula-V.

[0072] Pharmaceutically acceptable acid (HA) can be selected from the group consisting of hydrochloric acid, hydrobromic acid, phosphoric acid, oxalic acid, citric acid, maleic acid, and the like.

[0073] Organic solvent can be selected from alcohols such as methanol, ethanol, isopropanol, n-butanol, or mixtures thereof. Generally, reaction of Sitagliptin of Formula-I with pharmaceutically acceptable acid can be carried out at a temperature of 60°C to 80°C.

[0074] Pharmaceutically acceptable salt of Sitagliptin of Formula-V can be isolated by any technique of isolation known in the prior art, preferably by stepwise cooling. For example, the mixture can be cooled from about reflux temperature of solvent to ambient temperature followed by to -10°C to 10°C over a period of about 10 mins to about 1 hour, to about 10 hours or longer to obtain pharmaceutically acceptable salt of Sitagliptin of Formula-V.

[0075] In the first embodiment of step d), obtained Sitagliptin of Formula-I or pharmaceutically acceptable salt thereof is having purity greater than 99.9%, more preferably 99.99% by HPLC (High-performance liquid chromatography) and having chiral purity of 100% ee.

[0076] In the first embodiment of step d), content of nitrosamine impurity, Nitroso-STG- 19 (known as NTTP) in the obtained Sitagliptin of Formula-I or pharmaceutically acceptable salt thereof is less than 0.3 ppm, preferably less than 0.1 ppm.

[0077] Present invention provides excellent control of genotoxic impurities inclusive of nitrosamine impurity, Nitroso-STG-19.

[0078] In the first embodiment of step e), aqueous layer obtained in step c) can be continuously recycled in next batches to obtain Sitagliptin of Formula-I or pharmaceutically acceptable salt thereof by reacting the said aqueous layer with compound of the Formula-II followed by steps b) to d).

[0079] Present invention provides highly pure Sitagliptin of Formula-I or pharmaceutically acceptable salt thereof by recycling aqueous layer for at least 5 times.

[0080] Second embodiment of the present invention provides a process for the preparation of Sitagliptin hydrochloride monohydrate of Formula- III,

[0081] [Formula-Ill] comprising the steps of: a) dissolving Sitagliptin hydrochloride of Formula-IV

[0082] [Formula-IV] in methanol and water by heating up to reflux temperature; b) adding methyl tert-butyl ether to the mixture of step a); and c) isolating Sitagliptin hydrochloride monohydrate of Formula-Ill.

[0083] Sitagliptin hydrochloride of Formula-IV can be obtained by processes known in the prior art or by process of first embodiment of present invention.

[0084] In the second embodiment of step a), dissolution of Sitagliptin hydrochloride of Formula-IV in methanol and water can be carried out by heating the reaction mass to a temperature of 40°C to reflux temperature.

[0085] In the second embodiment of step a), volume of water used with respect to compound of the Formula-IV can be 2.0 volume to 3.0 volume.

[0086] In the second embodiment of step a), volume of methanol used with respect to compound of the Formula-IV can be 0.1 volume to 0.3 volume.

[0087] In the second embodiment of step a), solution obtained in step a) can be hot filtered and washed with hot methanol. In the second embodiment of step b), addition of methyl tert-butyl ether can be carried out at a room temperature of 20°C to 40°C.

[0088] In the second embodiment of step b), volume of methyl tert-butyl ether used with respect to compound of the Formula-IV can be 4.0 volume to 5.0 volume.

[0089] In the second embodiment of step c), isolation of Sitagliptin hydrochloride monohydrate of Formula-Ill can be carried out by any technique of isolation known in the art, preferably by cooling to a temperature of -10°C to 10°C over a period of about 10 mins to about 1 hour, to about 10 hours or longer followed by filtration at the same temperature.

[0090] In the second embodiment of step c), obtained Sitagliptin hydrochloride monohydrate of Formula-Ill can be further dried by any of the process known in the art. Drying may be carried out using equipment such as a tray dryer, vacuum oven, air oven, fluidized bed dryer, spin flash dryer, flash dryer, or the like, at atmospheric pressure or under reduced pressure. Drying may be carried out at temperatures less than about 100°C, less than about 60°C, less than about 40°C, or any other suitable temperatures, at atmospheric pressure or under reduced pressure, and in the presence or absence of an inert atmosphere such as nitrogen, argon, neon, or helium. The drying may be carried out for any desired time periods to achieve a desired purity of the product, such as, for example, about 1 to about 15 hours, or longer.

[0091] In the second embodiment of step c), obtained Sitagliptin hydrochloride monohydrate of Formula-Ill is having purity greater than 99.9%, more preferably 99.99% by HPLC (High-performance liquid chromatography) and having chiral purity of 100% ee.

[0092] In the second embodiment of step c), content of nitrosamine impurity, Nitroso- STG-19 (known as NTTP) in the obtained Sitagliptin hydrochloride monohydrate of Formula-Ill is less than 0.3 ppm, preferably less than 0.2 ppm, more preferably less than 0.1 ppm, most preferably less than 0.05 ppm. Process provides excellent control of genotoxic impurities inclusive of nitrosamine impurity, Nitroso-STG- 19, and offers highly pure and stable Sitagliptin hydrochloride monohydrate having 99.9% purity.

[0093] In the second embodiment of step c), obtained Sitagliptin hydrochloride monohydrate of Formula-Ill is having water content less than 5%, preferably less than 4%.

[0094] Sitagliptin hydrochloride, Sitagliptin phosphate or hydrate thereof obtained according to present invention controls impurity of Formula-B (herein after Impurity-B),

[0095] [Formula-B] below 0.5 ppm, preferably below 0.3 ppm.

[0096] The present invention provides highly pure Sitagliptin Hydrochloride or hydrates thereof and Sitagliptin phosphate or hydrates thereof having less than 0.5 ppm impurity-B, preferably less than 0.3 ppm impurity-B.

[0097] The present invention also provides highly pure Sitagliptin Hydrochloride or hydrates thereof and Sitagliptin phosphate or hydrates having less than 0.3 ppm NTTP impurity, preferably less than 0.1 ppm NTTP impurity.

[0098] Prior art fails to obtain and provide specific range of impurity-B and NTTP impurity. It is very important to control impurity-B in the process as it may result in the formation of NTTP impurity. Thus, the present invention controls the said impurity, which results in the highly pure API.

[0099] EXAMPLES:

[0100] Following examples are given by way of illustration. It may be understood for the person skilled in the art that these examples are only typical embodiments of the invention and are not therefore considered to be limiting the scope of the present invention.

[0101] Example 1: Preparation of Sitagliptin Hydrochloride

[0102] Dimethyl sulphoxide (150 g), purified water (150 g) and monoisopropylamine (22.5 g) were stirred together at 10°C to 20°C. The pH of the resulting mixture was adjusted to 9.0 to 10.0 using Cone, hydrochloric acid. The resulting mixture was heated to 45°C to 50°C and pyridoxal phosphate (0.25 g) followed by transaminase enzyme (1.5 g) were added to the resulting mixture. Ketoamide of Formula- II (50 g) was added in lots to the resulting mixture and pH was adjusted between 9.0 to 10.0 after addition of each lot using monoisopropyl amine. The resulting mixture was stirred at 45 °C to 50°C for 18 hours by maintaining pH of 9.0 to 10.0. After completion of reaction, the reaction mixture was cooled to room temperature and isopropyl acetate (300 mL) was added to the reaction mixture. Resulting mixture was stirred and allowed layers to separate.

[0103] The resulting organic layer was kept aside, and aqueous layer was extracted with isopropyl acetate (150 mL). The resulting aqueous layer was kept aside and was used continuously for the next recycling process.

[0104] Combined organic layer was washed with 20% aqueous sodium chloride solution (2 x 50 mL) followed by purified water (3 x 50 mL). Resulting combined organic layer was completely distilled to obtain Sitagliptin.

[0105] Obtained Sitagliptin was dissolved in isopropyl alcohol (150 mL) at 40°C to 45 °C. Cone, hydrochloric acid (15 mL) was added to resulting solution at 40- 45°C. Resulting mixture was heated to 70°C to 75°C for 1 hour and then gradually cooled to -5°C to-10°C. The resulting mixture was then filtered and washed with isopropanol. The product was dried under reduced pressure to afford Sitagliptin Hydrochloride (39.8 g)

[0106] HPLC purity: 99.99% and chiral purity: 100% ee.

[0107] NTTP impurity: 0.1431 ppm

[0108] The aqueous layer from the above process containing enzyme, pyridoxal phosphate and isopropylamine hydrochloride was used in the next cycle to produce Sitagliptin Hydrochloride. Example 2: Recycling process for the preparation of Sitagliptin Hydrochloride pH of the aqueous layer obtained from Example 1 was adjusted to 9.0 to 10.0 using monoisopropylamine. Resulting mixture was heated to 45°C to 50°C and ketoamide of Formula- II (50 g) was added slowly lot wise by maintaining pH at 9.0 to 10.0. Resulting mixture was stirred at 45°C to 50°C for 18 hours.

[0109] After completion of reaction, the reaction mixture was cooled to room temperature and isopropyl acetate (300 mL) was added to the reaction mixture. Resulting mixture was stirred and allowed layers to separate.

[0110] The resulting organic layer was kept aside, and aqueous layer was extracted with isopropyl acetate (150 mL). The resulting aqueous layer was kept aside and was used for the next recycling process.

[0111] Combined organic layer was washed with 20% aqueous sodium chloride solution (2 x 50 mL) followed by purified water (3 x 50 mL). Resulting combined organic layer was completely distilled to obtain Sitagliptin.

[0112] Obtained Sitagliptin was dissolved in isopropyl alcohol (150 mL) at 40°C to 45 °C. Cone, hydrochloric acid (15 mL) was added to resulting solution at 40- 45°C. Resulting mixture was heated to 70°C to 75°C for 1 hour and then gradually cooled to -5°C to-10°C. The resulting mixture was then filtered and washed with isopropanol. The product was dried under reduced pressure to afford Sitagliptin Hydrochloride (38.6 g)

[0113] HPLC purity: 99.99% and chiral purity: 100% ee.

[0114] NTTP impurity: 0.1102 ppm

[0115] The aqueous layer from the above process containing enzyme, pyridoxal phosphate and isopropylamine hydrochloride was used in the next cycle to produce Sitagliptin Hydrochloride.

[0116] Example 3: Recycling Process for the preparation of Sitagliptin Hydrochloride The aqueous layer obtained from Example 2 which contains enzyme, pyridoxal phosphate, isopropyl amine hydrochloride was used in the next cycle by repeating process of example 2 to produce Sitagliptin Hydrochloride.

[0117] Yield: 40.77 g, HPLC purity: 99.99% and chiral purity: 100% ee.

[0118] NTTP impurity: 0.1071 ppm

[0119] Example 4: Recycling Process for the preparation of Sitagliptin Hydrochloride

[0120] The aqueous layer obtained from Example 3 which contains enzyme, pyridoxal phosphate, isopropyl amine hydrochloride was used in the next cycle by repeating process of example 2 to produce Sitagliptin Hydrochloride.

[0121] Yield: 40.6 g, HPLC purity: 99.99% and chiral purity: 100% ee.

[0122] NTTP impurity: 0.0994 ppm

[0123] Example 5: Recycling Process for the preparation of Sitagliptin Hydrochloride

[0124] The aqueous layer obtained from Example 4 which contains enzyme, pyridoxal phosphate, isopropyl amine hydrochloride was used in the next cycle by repeating process of example 2 to produce Sitagliptin Hydrochloride.

[0125] Yield: 39.0 g, HPLC purity: 99.99% and chiral purity: 100% ee.

[0126] NTTP impurity: 0.1695 ppm

[0127] Example 6: Recycling Process for the preparation of Sitagliptin Hydrochloride

[0128] The aqueous layer obtained from Example 5 which contains enzyme, pyridoxal phosphate, isopropyl amine hydrochloride was used in the next cycle by repeating process of example 2 to produce Sitagliptin Hydrochloride.

[0129] Yield: 40.0 g, HPLC purity: 99.99% and chiral purity: 100% ee. Example 7: Preparation of 7-[(3R)-3-amino-l-oxo-4-(2,4,5-trifhiorophenyl) butyl]-5,6,7,8- tetrahydro-3-(trifluoromethyl)-l,2,4-triazolo[4,3-a] pyrazine hydrochloride monohydrate (Sitagliptin Hydrochloride Monohydrate)

[0130] Sitagliptin Hydrochloride obtained from Example 1 (30 g) was dissolved in methanol (90 mL) by heating to a temperature of 50°C to 60°C. Resulting solution was hot filtered and purified water (4.2 mL) was added to resulting filtrate. Resulting mixture was cooled to 25°C to 35°C followed by addition of Methyl tert-butyl ether (120 mL). The resulting mixture was stirred at the same temperature for a period of 1.5 hours and then cooled to -5 °C to -10°C. The mixture was filtered and then washed with methyl tert-butyl ether (30 mL). The obtained solid was dried under reduced pressure to afford Sitagliptin Hydrochloride Monohydrate (28.1 g)

[0131] HPLC purity: 99.93, chiral purity: 100%, water Content 3.9%.

[0132] Example 8: Preparation of 7-[(3R)-3-amino-l-oxo-4-(2,4,5-trifhiorophenyl) butyl]-5,6,7,8- tetrahydro-3-(trifluoromethyl)-l,2,4-triazolo[4,3-a] pyrazine hydrochloride monohydrate (Sitagliptin Hydrochloride Monohydrate)

[0133] Sitagliptin Hydrochloride obtained from Example 2 (30 g) was used for the preparation of Sitagliptin Hydrochloride Monohydrate as per process given in Example 7

[0134] Yield: 27.85 g, HPLC purity: 99.98%, chiral purity: 100% ee, NTTP impurity: 0.05 ppm, Impurity-B: 0.19 ppm, water Content 3.7%.

[0135] Example 9: Preparation of 7-[(3R)-3-amino-l-oxo-4-(2,4,5-trifhiorophenyl) butyl]-5,6,7,8- tetrahydro-3-(trifluoromethyl)-l,2,4-triazolo[4,3-a] pyrazine hydrochloride monohydrate (Sitagliptin Hydrochloride Monohydrate)

[0136] Sitagliptin Hydrochloride obtained from Example 3 (30 g) was used for the preparation of Sitagliptin Hydrochloride Monohydrate as per process given in Example 7

[0137] Yield: 28.6 g, HPLC purity: 99.99%, chiral purity: 100% ee, NTTP impurity: 0.05 ppm, Impurity-B: 0.18 ppm, water Content 3.8%. Example 10: Preparation of 7-[(3R)-3-amino-l-oxo-4-(2,4,5-trifhiorophenyl) butyl]-5,6,7,8- tetrahydro-3-(trifluoromethyl)-l,2,4-triazolo[4,3-a] pyrazine hydrochloride monohydrate (Sitagliptin Hydrochloride Monohydrate)

[0138] Sitagliptin Hydrochloride obtained from Example 4 (30 g) was used for the preparation of Sitagliptin Hydrochloride Monohydrate as per process given in Example 7

[0139] Yield: 29.3 g, HPLC purity: 99.99%, chiral purity 100% ee, NTTP impurity: 0.05 ppm, Impurity-B: 0.24 ppm, water Content: 3.3%.

[0140] Example 11: Preparation of 7-[(3R)-3-amino-l-oxo-4-(2,4,5-trifhiorophenyl) butyl]-5,6,7,8- tetrahydro-3-(trifluoromethyl)-l,2,4-triazolo[4,3-a] pyrazine hydrochloride monohydrate (Sitagliptin Hydrochloride Monohydrate)

[0141] Sitagliptin Hydrochloride obtained from Example 5 (30 g) was used for the preparation of Sitagliptin Hydrochloride Monohydrate as per process given in Example 7

[0142] Yield: 29.6 g, HPLC purity: 99.99%, chiral purity: 100% ee, NTTP impurity: 0.04 ppm, Impurity-B: 0.24 ppm, water Content 3.6%.

[0143] Sitagliptin hydrochloride Monohydrate is analogously prepared by method of example-1 to 11 on commercial scale (140 Kg)

[0144] Results of obtained Sitagliptin hydrochloride Monohydrate are summarized below-

[0145] Batch-1: HPLC purity: 99.99%, chiral purity: 100% ee, NTTP impurity: Not detected, Impurity-B: 0.1918 ppm,

[0146] Batch-2: HPLC purity: 99.99%, chiral purity: 100% ee, NTTP impurity: Not detected, Impurity-B: 0.1893 ppm,

[0147] Batch-3: HPLC purity: 99.99%, chiral purity: 100% ee, NTTP impurity: Not detected, Impurity-B: 0.2436 ppm,

[0148] Batch-4: HPLC purity: 99.99%, chiral purity: 100% ee, NTTP impurity: Not detected, Impurity-B: 0.2475 ppm. Sitagliptin Phosphate Monohydrate is analogously prepared by method of example- 1 to 11 by replacing cone. Hydrochloric acid to Phosphoric acid except purification of Sitagliptin Phosphate Monohydrate.

[0149] Sitagliptin Phosphate Monohydrate is purified by heating Sitagliptin Phosphate Monohydrate in presence of isopropanol- water at 75°C to 80°C, followed by charcoal treatment and cooling at 0°C to 5°C to obtain a Sitagliptin Phosphate Monohydrate.

[0150] Results of obtained Sitagliptin Phosphate Monohydrate are summarized below-

[0151] Batch-1: HPLC purity: 99.99%, chiral purity: 100% ee, NTTP impurity: 0.0017 ppm.

[0152] Batch-2: HPLC purity: 99.99%, chiral purity: 100% ee, NTTP impurity: 0.0017 ppm.

[0153] Batch-3: HPLC purity: 99.99%, chiral purity: 100% ee, NTTP impurity: 0.0046 ppm.

[0154] Batch-4: HPLC purity: 99.99%, chiral purity: 100% ee, NTTP impurity: 0.0087 ppm.

[0155] Advantages of the present invention:

[0156] 1. Process allows continuous recycling and re-use of once used transaminase enzyme without immobilization, thus making the production cost effective by saving the expenditure required for setting the additional dedicated infrastructure required for immobilization as well as minimizing the requirements of additional space, material, and utilities.

[0157] 2. Process allows recycling to be repeated at least 5 times to produce Sitagliptin or pharmaceutically acceptable salts thereof without loss in yield, purity, or enzyme activity and without the need of additional topping of enzyme, cofactor as well as water miscible organic solvent to the reaction mass, thereby making the process substantially economical. Process avoids the use of additional buffer such as triethanolamine, thereby additionally reducing the cost of production. Residual Solvent Content of DMSO, isopropyl acetate and isopropyl alcohol in Sitagliptin Hydrochloride Monohydrate is below the level of detection (Not Detectable). Current process avoids the additional step of removal of acetone byproduct from the reaction mass without affecting the reaction to proceed to completion. Current process provides excellent control of nitrosamine NTTP impurity controlling the content of NTTP impurity below the level of 0.3 ppm in the parent as well as subsequent production batches of Sitagliptin or its salts obtained by continuous recycling of enzyme and provides highly pure and stable Sitagliptin or pharmaceutically acceptable salt thereof having around 99.9% purity at the level of crude only before carrying out any purification or crystallization procedure.

Claims

We Claim:

1. A continuous recyclable enzymatic process for the preparation of highly pure Sitagliptin of Formula-I,[Formula-I] or pharmaceutically acceptable salts thereof comprising the steps of: a) reacting compound of Formula-II,[Formula-II] with amine donor using transaminase enzyme, cofactor in water and water miscible organic solvent in absence of buffer; b) adding water immiscible organic solvent to the reaction mixture obtained in step a); c) separating the organic layer and aqueous layer from mixture obtained in step b); d) obtaining highly pure Sitagliptin of Formula-I or pharmaceutically acceptable salt thereof from the organic layer obtained in step c); and e) continuously recycling aqueous layer obtained in step c) to produce next batches of Sitagliptin of Formula-I or pharmaceutically acceptable salt thereof by reacting the said aqueous layer with compound of the Formula- II followed by steps b) to d).

2. The process as claimed in claim 01; wherein amine donor is selected from the group consisting of monoisopropylamine, isobutyl amine, 2-methyl benzyl amine, diphenyl methyl amine, any C-substituted isopropyl amine, alanine,ortho-xylenediamine, 1 -phenylethylamine, 3 -aminocyclohexa- 1,5- dienecarboxylic acid, 1,2-diaminoethane, 1 ,4-diaminobutane and 1,5- diaminopentane.

3. The process as claimed in claim 01; wherein transaminase enzyme is selected from recombinant or genetically engineered transaminase enzyme.

4. The process as claimed in claim 01; wherein cofactor is selected from the group consisting of Vitamin B6 family including pyridoxal, pyridoxine, pyridoxamine and their respective phosphorylated derivatives such as pyridoxine 5'-phosphate, pyridoxal 5'-phosphate and pyridoxamine 5'- phosphate.

5. The process as claimed in claim 01; wherein water miscible organic solvent is selected from the group consisting of dimethyl sulfoxide (DMSO), ethyl acetate, chloroform, methylene dichloride (MDC), acetone, methanol, ethanol, or isopropanol or mixture thereof and water immiscible organic solvent is selected from the group consisting of alkyl ester such as ethyl acetate, isopropyl acetate, isobutyl acetate, tertiary butyl acetate or mixture thereof; ether such as diisopropyl ether, methyl isopropyl ether, methyl tert-butyl ether (MTBE); water immiscible alcohols such as n-butanol, tert-butanol, cyclohexanol or mixtures thereof and 2-methyl tetrahydrofuran or mixture thereof.

6. A process for the preparation of Sitagliptin hydrochloride monohydrate of Formula-Ill[Formula-Ill] comprising the steps of: a) dissolving Sitagliptin hydrochloride of Formula-IV,[Formula-IV] in methanol and water by heating up to reflux temperature; b) adding methyl tert-butyl ether to the mixture; and c) isolating Sitagliptin hydrochloride monohydrate of Formula IV.

7. Sitagliptin hydrochloride or hydrate thereof having less than 0.1 ppm NTTP impurity of Formula-A,[Formula-A] and less than 0.5 ppm of impurity-B or salt thereof,[impurity-B].

8. Sitagliptin hydrochloride or hydrate as claimed in claim 7, wherein impurity-B or salt thereof is less than 0.3 ppm.

9. Sitagliptin phosphate or hydrate thereof having less than 0.1 ppm NTTP impurity of Formula-A,[Formula-A] and less than 0.5 ppm of impurity-B or salt thereof,[Impurity-B] 10. Sitagliptin phosphate or hydrate as claimed in claim 9, wherein impurity-B or salt thereof is less than 0.3 ppm.

Citation Information

Patent Citations

  • Recyclable biocatalytic process for preparation of sitagliptin

    IN202211016043A

  • Processes for the preparation of sitagliptin and pharmaceutically acceptable salts thereof

    WO2020109938A1

Cited By

  • Preparation method of sitagliptin base

    CN121342832A